New Classes of Non-Enzymatic Inhibitors of Syk
Author Information
Author(s): Villoutreix Bruno O., Laconde Guillaume, Lagorce David, Martineau Pierre, Miteva Maria A., Dariavach Piona
Primary Institution: INSERM, U973, Université Paris Diderot, Paris, France
Hypothesis
Can we design drug-like compounds that inhibit Syk's interactions without affecting its catalytic activity?
Conclusion
The study identified several bioactive compounds that inhibit Syk's interactions and have potential for treating allergic and autoimmune disorders.
Supporting Evidence
- 85 compounds were selected based on their ability to inhibit the binding of an antibody to Syk.
- 10 compounds inhibited mast cell degranulation with IC50 values ≤10 µM.
- The identified compounds showed good potential for oral bioavailability.
Takeaway
Researchers found new compounds that can help treat allergies by stopping a protein called Syk from working too much, without blocking its main job.
Methodology
The study used virtual screening of 500,000 molecules followed by in vitro assays to evaluate their effects on Syk.
Limitations
The study primarily focused on a specific binding pocket and may not account for all potential interactions of Syk.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website